BRD3731
Based on 2 publication(s) in Google Scholar
BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.18%
- CAS No.: 2056262-07-6
- 화학식: C24H31N3O
- 분자량:377.52
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Reprogramming Compound Library
HY-L039
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Antidepressant Compound Library
HY-L108
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Metabolic Enzyme Compound Library
HY-L146
-
Cysteine Targeted Covalent Library
HY-L153
-
Highly Selective Inhibitors Library
HY-L158
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Kinase Inhibitor Library
HY-L009
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) BRD3731
More
Biological Activity
|
GSK-3β 15 nM (IC50) |
GSK-3α 215 nM (IC50) |
BRD3731 is a GSK3β- selective inhibitor extracted from patent US20160375006A1, compound example 272[1].
?
BRD3731 (1-10 μM; 24 hours) inhibits the phosphorylation of CRMP2 in SH-SY5Y cells[1].
?
BRD3731 (20 μM; 24 hours) decreases β-catenin S33/37/T41 phosphorylation and induces β-catenin S675 phosphorylation in HL-60 cells[2].
?
BRD3731 (10-20 μM; 7-10 days) impairs colony formation in TF-1 and increases colony forming ability in the MV4-11 cell line[2]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2056262-07-6
-
Appearance Solid
-
분자량 377.52
-
화학식 C24H31N3O
-
Color Light yellow to yellow
-
SMILES
O=C1C2=C(N=C3C([C@]2(C)C4=CC=CC=C4)=C(CC(C)(C)C)NN3)CC(C)(C)C1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Clin Epigenetics
DNA hypermethylation of PLTP mediated by DNMT3B aggravates vascular dysfunction in diabetic retinopathy via the AKT/GSK3β signaling pathway. [Abstract]2025 May 17;17(1):82. PMID: 40380281 -
용액&용해도
DMSO : 50 mg/mL (132.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (13.24 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (13.24 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Edward Scolnick, et al. Uses of paralog-selective inhibitors of gsk3 kinases. US20160375006A1.
[2]. Wagner FF, et, al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431):eaam8460. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6489 mL | 13.2443 mL | 26.4887 mL | 66.2217 mL |
| 5 mM | 0.5298 mL | 2.6489 mL | 5.2977 mL | 13.2443 mL | |
| 10 mM | 0.2649 mL | 1.3244 mL | 2.6489 mL | 6.6222 mL | |
| 15 mM | 0.1766 mL | 0.8830 mL | 1.7659 mL | 4.4148 mL | |
| 20 mM | 0.1324 mL | 0.6622 mL | 1.3244 mL | 3.3111 mL | |
| 25 mM | 0.1060 mL | 0.5298 mL | 1.0595 mL | 2.6489 mL | |
| 30 mM | 0.0883 mL | 0.4415 mL | 0.8830 mL | 2.2074 mL | |
| 40 mM | 0.0662 mL | 0.3311 mL | 0.6622 mL | 1.6555 mL | |
| 50 mM | 0.0530 mL | 0.2649 mL | 0.5298 mL | 1.3244 mL | |
| 60 mM | 0.0441 mL | 0.2207 mL | 0.4415 mL | 1.1037 mL | |
| 80 mM | 0.0331 mL | 0.1656 mL | 0.3311 mL | 0.8278 mL | |
| 100 mM | 0.0265 mL | 0.1324 mL | 0.2649 mL | 0.6622 mL |
BRD3731 Related Classifications
HY-124607B Related Classifications
Powered by Bioz